Helus Pharma closed at $9.10 on Nov 6, up 8.46%, 35.1% below its highest close since Jan 5. Volume of 603.4K shares was 0.38× its 20-day average (below normal).
Split-adjusted performance: -15.1% over one month, +71.4% over six months.
Short interest was 3.0M shares at the Oct 15 settlement, down 13.1% from the prior report (6.0% of float, 1.9 days to cover).
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety.
What is HELP's market cap?
$664.93M, based on the Nov 6 close of $9.10.
How much of HELP is sold short?
3.0M shares, 6.0% of float, as of Oct 15, 2026.
About Helus Pharma
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
